How CareDx, Inc (NASDAQ:CDNA) Can Impact Your Portfolio Volatility

If you own shares in CareDx, Inc (NASDAQ:CDNA) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of volatility. Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. The first category is company specific volatility. This can be dealt with by limiting your exposure to any particular stock. The second type is the broader market volatility, which you cannot diversify away, since it arises from macroeconomic factors which directly affects all the stocks on the market.

Some stocks mimic the volatility of the market quite closely, while others demonstrate muted, exagerrated or uncorrelated price movements. Beta is a widely used metric to measure a stock's exposure to market risk (volatility). Before we go on, it's worth noting that Warren Buffett pointed out in his 2014 letter to shareholders that 'volatility is far from synonymous with risk.' Having said that, beta can still be rather useful. The first thing to understand about beta is that the beta of the overall market is one. A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.

View our latest analysis for CareDx

Advertisement

What we can learn from CDNA's beta value

Looking at the last five years, CareDx has a beta of 0.81. The fact that this is well below 1 indicates that its share price movements haven't historically been very sensitive to overall market volatility. This means that -- if history is a guide -- buying the stock would reduce the impact of overall market volatility in many portfolios (depending on the beta of the portfolio, of course). Share price volatility is well worth considering, but most long term investors consider the history of revenue and earnings growth to be more important. Take a look at how CareDx fares in that regard, below.

NasdaqGM:CDNA Income Statement, February 3rd 2020
NasdaqGM:CDNA Income Statement, February 3rd 2020

How does CDNA's size impact its beta?

With a market capitalisation of US$1.0b, CareDx is a small cap stock. However, it is big enough to catch the attention of professional investors. Small companies often have a high beta value, but they can be heavily influenced by company-specific events. This might explain why this stock has a low beta.

What this means for you:

One potential advantage of owning low beta stocks like CareDx is that your overall portfolio won't be too sensitive to overall market movements. However, this can be a blessing or a curse, depending on what's happening in the broader market. In order to fully understand whether CDNA is a good investment for you, we also need to consider important company-specific fundamentals such as CareDx’s financial health and performance track record. I urge you to continue your research by taking a look at the following:

  1. Future Outlook: What are well-informed industry analysts predicting for CDNA’s future growth? Take a look at our free research report of analyst consensus for CDNA’s outlook.
  2. Past Track Record: Has CDNA been consistently performing well irrespective of the ups and downs in the market? Go into more detail in the past performance analysis and take a look at the free visual representations of CDNA's historicals for more clarity.
  3. Other Interesting Stocks: It's worth checking to see how CDNA measures up against other companies on valuation. You could start with this free list of prospective options.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

M
mitchell_lawler
mitchell_lawler

Berkshire sold Visa and Mastercard. Ackman just bought both. So whose "smart money" are you actually following?

137
m
marcus_l38oa

American Express is the bigger bet of Buffet than Mastercard and Visa. They are still holding it.

z
zoe_vi5fn

lol. what we should be discussing is Berkshire's cash pile. Close to 400 billion now.

Andrew Legget

Great earnings season, but are the earnings real?

Great earnings season, but are the earnings real? cover
At first glance, this was the strongest earnings season in years. But when you look at where the growth actually came from, the story splits into two very different pictures.
85

About NasdaqGM:CDNA

CareDx

Provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally.

Flawless balance sheet with solid track record.

Advertisement

Weekly Picks

LO
Lou_Basenese
ONCY logo
Lou_Basenese on Oncolytics Biotech ·

The Team Behind a $2 Billion Johnson & Johnson (JNJ) Deal Just Took Over This $105 Million Cancer Biotech

Fair Value:US$3.576.0% undervalued
45 users have followed this narrative
0 users have commented on this narrative
12 users have liked this narrative
AN
andrei9868
Emerging Author
NOW logo
andrei9868 on ServiceNow ·

The Platform Turning Enterprise Chaos into Autonomous Workflows

Fair Value:US$17015.9% undervalued
14 users have followed this narrative
2 users have commented on this narrative
2 users have liked this narrative
JO
John_Eric
Emerging Author
VST logo
John_Eric on Vistra ·

Vistra Fell 38%. Adjusted EBITDA Rose 31%. Here's the $472 Million Reason They Disagree.

Fair Value:US$291.8752.7% undervalued
7 users have followed this narrative
0 users have commented on this narrative
5 users have liked this narrative
HA
HarishPK
Emerging Author
EVER logo
HarishPK on EverQuote ·

EverQuote and an Asymmetric Investment Opportunity

Fair Value:US$36.0931.2% undervalued
4 users have followed this narrative
1 users have commented on this narrative
3 users have liked this narrative

Updated Narratives

JO
John_Eric
V logo
John_Eric on Visa ·

Visa on Trial: The Berkshire Verdict, and Why I'm Overruling It

Fair Value:US$381.552.3% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
WO
Womble
APP logo
Womble on AppLovin ·

AppLovin's Future Looks Bright with 19% Revenue Growth

Fair Value:US$331.946.1% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
WO
Womble
NBIS logo
Womble on Nebius Group ·

Prepare for Nebius Group's Revenue to Soar by 49.8%

Fair Value:US$259.9723.2% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28022.3% undervalued
374 users have followed this narrative
9 users have commented on this narrative
17 users have liked this narrative
JO
John_Eric
Emerging Author
MELI logo
John_Eric on MercadoLibre ·

MercadoLibre and the Spreadsheet Trick That Decides Everything

Fair Value:US$7.31k73.2% undervalued
128 users have followed this narrative
3 users have commented on this narrative
18 users have liked this narrative
CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.9119.3% overvalued
217 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative

Trending Discussion